1st treatment for EGFR+ NSCLC with exon 19 deletions or exon 21 L858R mutations
RYBREVANT® + LAZCLUZE™ is the only chemotherapy-free treatment proven to reduce the risk of cancer growing or spreading by 30% compared with the current standard of care (osimertinib)*
At 23.7 months, half of the people receiving RYBREVANT® + LAZCLUZE™ lived without their cancer growing or spreading, compared with 16.6 months for osimertinib
These results are from a clinical trial where 858 people with advanced NSCLC with exon 19 deletion or exon 21 L858R received a first treatment of RYBREVANT® in combination with LAZCLUZE™ or a first treatment of osimertinib alone.
About the people in the clinical trial
- Most of the people never smoked (69%)
- Over half of the people were women (61%)
*Osimertinib is a preferred first treatment option for EGFR exon 19 deletion or exon 21 L858R mutations in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non–Small Cell Lung Cancer V.10.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed September 25, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
78% of people responded (tumors got smaller† or disappeared‡) with RYBREVANT® + LAZCLUZE™
RYBREVANT® + LAZCLUZE™
Tumors got smaller†: 73%
Tumors disappeared‡: 5%
Osimertinib
Tumors got smaller†: 70%
Tumors disappeared‡: 4%
Time that people responded (tumors got smaller† or disappeared‡)
Of people who responded, half were still responding at 25.8 months with RYBREVANT® + LAZCLUZE™ and 16.7 months with osimertinib.
†Tumors getting smaller may also be called a partial response. This means the tumor got measurably smaller but is still detectable.
‡Tumors disappearing may also be called a complete response. This does not necessarily mean the cancer has been cured.
Side effects
There are side effects that you may experience during treatment with RYBREVANT®.
Savings & Support
Once prescribed a RYBREVANT®-based treatment, connect with a Care Navigator for your support needs.
